Sensius
Sensius B.V. is a Dutch medical device company developing the modular Focus thermotherapy platform (FocusCore base unit with body-site applicators) that heats solid tumors to 40-44°C to enhance radiotherapy, chemotherapy, and immunotherapy efficacy, initially targeting head and neck cancer clinics across Europe, the UK, and the USA.
- Company typePrivate
- Founded2015
- HeadquartersRotterdam, Netherlands
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Sensius does
Sensius B.V. is a Dutch medical device company developing precision thermotherapy systems for solid tumor treatment, founded in 2015 as a spin-off from Erasmus MC Cancer Institute in Rotterdam. The company targets oncology departments at major cancer treatment centers, initially focused on head and neck cancer with planned expansion into breast cancer, melanoma, and sarcoma. Sensius's core value proposition is enhancing the efficacy of radiotherapy, chemotherapy, and immunotherapy by heating tumors to 40-44°C while preserving surrounding healthy tissue, addressing the 50% recurrence rate in head and neck cancer patients and reducing treatment toxicity without adding systemic side effects.
Sensius's platform centers on the FocusCore base unit, which houses 20 independently controlled microwave amplifiers, water cooling systems, and integrated control computers. Body-site specific applicators connect to the FocusCore: the FocusCollar for head and neck cancer (initial commercial product), with pipeline products including FocusCup (breast cancer with chemotherapy), FocusBlanket (melanoma with immunotherapy), and FocusExtremity (sarcoma for arms and legs). The FocusControl software, based on patented WaveAdapt technology, provides adaptive treatment planning customized per patient. Two patents protect the HyperCollar4D technology. Sensius holds ISO 13485:2016 certification (obtained February 2024), with regulatory filings planned for CE Mark in Europe, UKCA marking in early 2026, and IDE filing in the USA. Clinical evidence is being built through 70+ prototype treatments at Erasmus MC, with the TRIHAN trial demonstrating 81.8% complete response in recurrent HNC patients and a 50% improvement over radiotherapy alone.
Sensius operates a B2B enterprise sales model targeting hospitals and cancer centers, with revenue intended to come primarily through capital equipment sales of the Focus system plus body-site applicators. The go-to-market relies on clinical trial partnerships at leading academic centers (Erasmus MC, Charité Berlin, UK clinics, US clinics), followed by regulatory approval and reimbursement-driven adoption. Channel partners support international distribution: AMG Medtech covers the UK and Ireland, while Andromedic represents Sensius in Italy. The Netherlands has reimbursement in place, with roadmaps being developed for Germany, the UK, and the USA. Pre-commercial at present, Sensius is funded by €21.7M+ in equity and grants, with a €15M Series A completed in June 2025 led by GrayBella Capital and UCEA Capital Partners.
Sensius firmographics
Firmographics- Name
- Sensius
- Legal name
- Sensius B.V.
- Website
- https://sensiusthermotherapy.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Sensius B.V. is a Dutch medical device company developing the modular Focus thermotherapy platform (FocusCore base unit with body-site applicators) that heats solid tumors to 40-44°C to enhance radiotherapy, chemotherapy, and immunotherapy efficacy, initially targeting head and neck cancer clinics across Europe, the UK, and the USA.
- Ownership category
- akta.pro rank
Sensius industry classification
Industry- Product category
- Oncology Medical Devices
- NAICS
- Irradiation Apparatus Manufacturing (334517), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Radiation Therapy Planning & Simulation Imaging (CT Sim/MR Sim) (HLAHABAH)
- akta.pro secondary industry
- Radiation Oncology (HLAKAFAC)
Keywords
Where Sensius is headquartered
LocationHeadquarters
- HQ city
- Rotterdam
- HQ country
- Netherlands
- HQ region
- Europe
Offices1 record
Markets served
Sensius business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales
Revenue model
- Medical Device Sales (Focus System): Sensius generates revenue from selling its thermotherapy medical device system (FocusCore + applicators) to hospitals and cancer treatment centers. The system is modular, with a base unit and body-site specific applicators sold as add-ons. Pricing follows a capital equipment model typical for medical devices, with reimbursement enabling hospital procurement.
- Clinical Trial Services: Revenue may be generated through clinical trial support and product development collaborations with research institutions, funded via grants and partnership agreements.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels6 records
Sensius product offering
Product offeringCore offering
Sensius develops a precision thermotherapy medical device system that delivers controlled microwave hyperthermia (40-44°C) to solid tumors in combination with radiotherapy, chemotherapy, or immunotherapy. The modular Focus platform consists of the FocusCore base unit (height-adjustable bed, twenty independently controlled microwave amplifiers, water cooling, control computers) and body-site specific applicators (FocusCollar for head and neck cancer, FocusCup for breast cancer, FocusBlanket for melanoma, FocusExtremity for sarcoma). Treatment is planned and delivered via the FocusControl software based on patented WaveAdapt technology with MR-based temperature measurement.
Product overview
Sensius offers a modular thermotherapy platform consisting of the FocusCore base unit and body-site specific applicators (FocusCollar, FocusCup, FocusBlanket, FocusExtremity) with associated FocusControl treatment planning software. The FocusCore houses twenty independently controlled microwave amplifiers, water pumps, and control systems that power the various applicators. The FocusCollar is the initial commercial launch product for head and neck cancer, while FocusCup (breast cancer), FocusBlanket (melanoma), and FocusExtremity (sarcoma) are in the pipeline for expansion to other solid tumors. The system delivers targeted heating to tumors at 40-44°C in combination with radiotherapy, chemotherapy, or immunotherapy to enhance treatment efficacy.
Differentiator
Problem solved
Functional benefit
Brands
- FocusCollar: Body-site specific add-on to FocusCore for head and neck cancer treatment with positioning antennas and bolus
- FocusCup
- FocusBlanket
- FocusExtremity
- FocusCore
- FocusControl
Products and services
- FocusCore Base unit comprising a height-adjustable bed, twenty independently controlled microwave amplifiers, water pumps and cooling system, nurse station and control computers. The modular core system that powers all body-site specific applicators and contains all components needed for treatment of all tumor types.
- FocusCollar Body-site specific add-on to FocusCore for head and neck cancer treatment. Positions antennas around the target area and connects microwave energy to the body via a body-site specific bolus, redesigned with novel technology from Erasmus MC and TU-Delft for improved antenna-to-patient connection and focused energy delivery.
- FocusControl Software providing accurate treatment preparation and delivery, customized to individual patients. Based on WaveAdapt patented technology, includes automated steering of heat treatment using MR-based temperature measurement across the entire target volume.
- HyperCollar4D (Focus System) Next-generation thermotherapy device that increases effectiveness of radiotherapy for head and neck cancer by warming tumors to 43°C. The first device to achieve effective and cost-efficient hyperthermia treatments for head and neck cancer, protected by two patents (one granted, one filed).
- FocusCup Breast cancer applicator in development for use with chemotherapy, expanding the Focus product family to additional solid tumor types by enhancing chemotherapy efficacy through targeted thermotherapy.
- FocusBlanket Melanoma treatment applicator in development for use with immunotherapy, expanding thermotherapy applications to skin cancer by activating immune response through controlled heating.
- FocusExtremity Sarcoma treatment applicator for arms and legs in development for use with chemotherapy, extending thermotherapy to extremity tumors.
Quantifiable outcome
- 50% improvement in complete response rate when thermotherapy added to radiotherapy (vs radiotherapy alone in TRIHAN trial)
- +5 more outcomes
Companies that use Sensius
Customer profileNamed customers8 records
Segments4 records
Ideal customer profiles2 records
Sensius technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature7 records
Sensius partnerships and signals
Strategic signalPartnerships
Twelve partnerships are on record, tiered core.
- US Clinical Trial Network (6 clinics)core6 US-based clinics participated in Phoenix meeting (ASTRO) to discuss Phase I-III clinical protocols for FDA clearance and reimbursement. Led by Jason Molitoris (UoM Baltimore) with Mark Hurwitz (MC Westchester) presenting mechanism of action.
- TU/e (Eindhoven University of Technology)coreSENS-THERM project partner (electromagnetic sensing, video control, metamodeling in thermotherapy for H&N cancers). Prof. Maarten Paulides leads EM4C&C lab at TU/e. Co-founder Prof. Paulides maintains academic appointment.
- UK Thermotherapy Special Interest GroupcoreMulti-clinic collaboration including Kings College London, Queen Elizabeth Hospital Birmingham, and Clatterbridge Cancer Centre, with NHS radiotherapy ODN and MacMillan Cancer Support representation. Organized by Prof. Bodis and AMG Medtech.
- AndromediccoreLetter of Intent signed at ESHO Cologne for marketing and sales in Italy. Andromedic is an established hyperthermia device manufacturer selling capacitive devices in Europe and SE Asia. Will represent Sensius as sales agent and collaborate on Italian oncology society engagement and clinical trial design for reimbursement.
- Prof. Stephan Bodis (Medical Advisor)coreProf. Em. Stephan Bodis serves as senior medical advisor. Previously head of department at Kantonspital Aarau, where he established hyperthermia reimbursement in Switzerland and built Swiss Hyperthermia Network of 15 clinics. Brings 20 years of hyperthermia leadership.
- Inselspital BerncoreLetter of Intent for cooperation on thermotherapy introduction for head and neck cancer. University hospital and tertiary specialized center for H&N cancer in Switzerland. Dr. Emanuel Stutz involved.
- Kantonsspital AaraucoreLetter of Intent for cooperation on thermotherapy for head and neck cancer. Driver of Swiss Hyperthermia Network (15 clinics). Prof. Dr. med. Oliver Riesterer chairs radiotherapy. Prof. Stephan Bodis previously built hyperthermia department here.
- AMG Medtech LimitedcoreUK and Ireland commercial partnership. AMG represents Sensius in these territories and aims to build a network of clinics for clinical trials followed by nationwide adoption. Medical imaging consultancy with extensive radiotherapy community network.
- Charité Universitätsmedizin BerlincoreLOI signed for cooperation in product development, consultancy, reimbursement, and clinical trials. Prof. Dr. Daniel Zips (Head of department) leads. Will conduct first-in-patient testing for CE marking, followed by clinical trials and German reimbursement.
- Technobis High Tech SolutionscorePartnership for development and production of Sensius thermotherapy device, transitioning prototype to commercial medical device. Technobis specializes in medical device development.
- Motive EngineeringcorePartnership for medical device software development as part of consortium with Technobis and Sensius. Extensive experience in medical device software.
- Erasmus MC Cancer InstitutecoreStrategic partnership based on next-generation thermotherapy technology developed at Erasmus MC and commercialized by Sensius. Includes international clinical trial leadership, sponsorship for a PhD, Center of Excellence establishment, and intended sales contract for FocusCollar. Erasmus MC has developed the core technology over two decades with 70+ patients treated. Spin-off from Erasmus MC formalized April 2015.
Scale indicators9 records
Recent moves9 records
Expansion highlights6 records
Sensius competitors and assessment
Company assessmentDirect peers
- Pyrexar Medical: Pyrexar Medical (formerly BSD Medical/Perseon Medical) is a US-based manufacturer of microwave and radiofrequency hyperthermia systems for cancer treatment, including systems used in conjunction with radiotherapy for various solid tumors. It is the most direct competitor to Sensius in the microwave hyperthermia device category.
- MagForce AG: MagForce is a German medical device company that commercializes NanoTherm therapy, a magnetic nanoparticle-based hyperthermia approach for glioblastoma and prostate cancer. It uses a different energy modality (magnetic vs. microwave) but competes in the same oncology hyperthermia space as Sensius.
- Oncotherm Kft. Oncotherm is a Hungarian-German manufacturer of capacitive hyperthermia devices used as adjuvants to radiotherapy and chemotherapy for solid tumors. It is a direct competitor in the oncology hyperthermia equipment market with established European sales.
- Andromedic: Andromedic is an Italian hyperthermia device manufacturer selling capacitive hyperthermia systems in Europe and Southeast Asia. It is both a Sensius channel partner for Italy and a direct competitor in the broader hyperthermia device category.
- Celsius42 GmbH: Celsius42 is a German medical device company developing hyperthermia systems for cancer treatment, with a focus on modular, clinically integrated solutions. It directly competes with Sensius in the European precision thermotherapy space.
Emerging players
- Novocure Ltd. Novocure develops Tumor Treating Fields (TTFields), a non-invasive modality for solid tumors including head and neck cancer. It competes with Sensius for oncology budget and radiotherapy workflow integration rather than directly in hyperthermia.
- RefleXion Medical: RefleXion Medical develops biology-guided radiotherapy (BgRT) systems that integrate PET imaging with radiation delivery for solid tumors including head and neck cancer. It represents an emerging alternative modality competing for the same oncology patient population Sensius targets.
Broad incumbents
- Elekta AB: Elekta is a global leader in radiation therapy and radiosurgery equipment (linacs, brachytherapy) with which Sensius's thermotherapy workflow must integrate. Sensius's Head of Product Dan Fristedt previously developed linear accelerators at Elekta, and Sensius devices are designed for radiotherapy workflow compatibility.
- Accuray Incorporated: Accuray develops the CyberKnife and TomoTherapy radiation therapy systems used in head and neck cancer treatment. It competes for radiotherapy capital budgets and workflow slots where Sensius thermotherapy would be deployed.
- Varian Medical Systems (Siemens Healthineers): Varian (now part of Siemens Healthineers) is the dominant global supplier of linear accelerators and radiotherapy treatment planning software. Sensius's WaveAdapt software and FocusControl are designed to integrate with Varian/Elekta-style radiotherapy workflows, and Varian represents both a partner opportunity and a competitive incumbent.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
Sensius social profiles
Digital presenceSensius compliance and trust
Trust signalCompliance2 records
Sensius financial estimates
Financial estimateRevenue estimate
Valuation estimate
Sensius leadership team
Management profileNumber of profiles
Profiles15 records
Sensius funding detail
Funding detailFunding overview
Funding rounds6 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Sensius M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Sensius
What does Sensius do?
Sensius develops a precision thermotherapy medical device system that delivers controlled microwave hyperthermia (40-44°C) to solid tumors in combination with radiotherapy, chemotherapy, or immunotherapy. The modular Focus platform consists of the FocusCore base unit (height-adjustable bed, twenty independently controlled microwave amplifiers, water cooling, control computers) and body-site specific applicators (FocusCollar for head and neck cancer, FocusCup for breast cancer, FocusBlanket for melanoma, FocusExtremity for sarcoma). Treatment is planned and delivered via the FocusControl software based on patented WaveAdapt technology with MR-based temperature measurement.
Is Sensius a public or private company?
Sensius is a private company. It is classified as venture growth investor backed and is currently operating.
When was Sensius founded?
Sensius was founded in 2015. It employs 1 to 10 people.
Where is Sensius based?
Sensius is headquartered in Rotterdam, Netherlands, in the Europe region.
How does Sensius make money?
Two revenue lines are on record. Medical Device Sales (Focus System) is the primary driver. The others are clinical Trial Services.
Who are Sensius's main competitors?
Direct peers on record are Pyrexar Medical, MagForce AG, Oncotherm Kft., Andromedic and Celsius42 GmbH. Emerging players are Novocure Ltd. and RefleXion Medical. Broad incumbents are Elekta AB, Accuray Incorporated and Varian Medical Systems (Siemens Healthineers).
Does Sensius have an API?
No public API is recorded for Sensius.
What industry is Sensius in?
Sensius's product category is Oncology Medical Devices. Its primary akta.pro industry code is HLAHABAH, Radiation Therapy Planning & Simulation Imaging (CT Sim/MR Sim), with a secondary code of HLAKAFAC, Radiation Oncology. Its NAICS code is 334517 and its SIC code is 3841.